Cowen analyst Ryan Blicker raised his price target on Tandem Diabetes (TNDM) to $85 from $70 as he views the near-term setup is attractive with Control-IQ likely to drive upside versus near-term estimates, UnitedHealth (UNH) could be a near-term catalyst, and the elevated short interest. Ryan reiterated his Outperform rating on Tandem Diabetes shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here